Current and Emerging Systemic Therapies for HCC: Clinical Evidence and Guideline Recommendations

Join us for this dynamic CME/CE/CPE-certified live webinar, in which an expert panel will discuss current guidance and emerging strategies for treating patients with early and advanced HCC. Sign up now!

Agenda

  • Recent Data on Frontline Treatment of Advanced HCC
  • Optimal Sequencing of Second-line Therapy and Beyond
  • Investigational Approaches on Resection and Locoregional Treatment
  • Audience Question and Answer Session

Events

Date / Time
Event Details

Faculty

Faculty
Adam Burgoyne, MD, PhD

Assistant Clinical Professor
Division of Hematology/Oncology
Department of Medicine
University of California, San Diego
UC San Diego Moores Cancer Center
La Jolla, California

Faculty
Lipika Goyal, MD

Assistant Professor of Medicine
Division of Hematology/Oncology
Department of Medicine
Harvard Medical School
Attending Physician
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Faculty
Stacey Stein, MD

Assistant Professor of Medicine
Department of Medical Oncology
Yale University
Medical Oncologist
GI Oncology
Yale Cancer Center
New Haven, Connecticut

Goal Statement
The goal of this program is to improve the knowledge and competence of learners in the optimal management of patients with HCC.

Target Audience
This educational program is intended for medical oncologists, surgical oncologists, pathologists, physician assistants, nurses, pharmacists, and other healthcare professionals who treat patients with HCC.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Evaluate clinical data on the use of systemic treatment approaches for patients with early or intermediate-stage HCC
  • Plan optimal, individualized care plans for patients with advanced HCC, both in the frontline and second-line treatment settings
  • Select patients who may benefit from ongoing clinical trials based on tumor characteristics, previous treatment, and patient characteristics and preferences
  • Develop strategies to identify and mitigate unique adverse events associated with novel targeted therapies in patients with HCC

Accreditation

Joint Accreditation Statement

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

NCCN designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
NCCN designates this educational activity for a maximum of 1.5 contact hours.

Continuing Pharmacy Education

NCCN designates this application-based continuing education activity for 1.5 contact hour (0.15 CEUs) of continuing education credit.
February 4 UAN: JA4008196-0000-22-017-L01-P
February 25 UAN: JA4008196-0000-22-025-L01-P

Attention Pharmacists:
You must complete the post-test and evaluation within 30 days of the activity. Continuing pharmacy education credit is reported to the CPE Monitor once the post-test and evaluation are completed. Before completing these requirements, be sure your NCCN profile has been updated with your NABP e-profile ID and date of birth or your credit cannot be reported. If you have not already done so, please complete your e-profile at https://nabp.pharmacy/ to obtain your NABP e-Profile ID.

Physician Assistants
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose all financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.

In addition, all content will be reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, will be fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. NCCN and Clinical Care Options, LLC do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of NCCN and Clinical Care Options, LLC. Please refer to the official prescribing information for each product for discussion of approved indication, contraindications, and warnings.